pharma · Gram-negative Bacterial Infections · SARS-CoV-2 Infection
Shionogi Inc. (U.S.)
Shionogi B.V.
Shionogi is a pharma organization headquartered in EU. Primary therapeutic focus areas include Gram-negative Bacterial Infections, SARS-CoV-2 Infection, SARS-CoV-2, Respiratory Syncytial Virus Infections, Late-onset Pomp
Company details
- Status
- Public
- HQ
- Florham Park, USA
- Founded
- 2001
- Employees
- 601
- Programs
- 6
- Drugs
- 8
- Patents
- 0
Quick answer
Shionogi is a pharma organization headquartered in EU. Primary therapeutic focus areas include Gram-negative Bacterial Infections, SARS-CoV-2 Infection, SARS-CoV-2, Respiratory Syncytial Virus Infections, Late-onset Pompe disease.. NovaPharmaNews links 6 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (4), phase 3 (2).
Company snapshot
Since 1878, we have been committed to developing new treatments to improve patients' lives worldwide. We are helping to address global health challenges such as antimicrobial resistance and COVID-19. Since the 1950s, we have discovered and introduced several novel antibiotics, as well as innovative medications for HIV and influenza. Today, we are developing an investigational oral antiviral for CO
- 6 active pipeline program(s) linked via ClinicalTrials.gov.
- 6 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for Shionogi Inc. (U.S.). Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19
- approval
FDA Approves Xocova: A Catalyst for Pharmaceutical M&A and Licensing
- approval
FDA Approves First Oral COVID-19 PEP Drug, Xocova
- approval
FDA Approves Ensitrelvir (XOCOVA) as First Oral Option for COVID-19 Post-Exposure Prophylaxis
Recent coverage
FDA Approves Ensitrelvir (XOCOVA) as First Oral Option for COVID-19 Post-Exposure Prophylaxis
The FDA has approved Shionogi's ensitrelvir (XOCOVA) as the first and only oral antiviral for post-exposure prophylaxis of COVID-19. This approval addresses a critical prevention gap and introduces a convenient five-day oral regimen.
FDA Approves First Oral COVID-19 PEP Drug, Xocova
The FDA has approved Shionogi's Xocova (ensitrelvir) as the first oral post-exposure prophylaxis (PEP) for COVID-19 in adults and adolescents aged 12 years and older. The approval is based on the Phase 3 SCORPIO-PEP trial.
FDA Approves Xocova: A Catalyst for Pharmaceutical M&A and Licensing
The FDA has approved Shionogi's Xocova, marking a significant development in COVID-19 prevention. This approval coincides with a surge in pharmaceutical industry mergers and licensing deals, signaling a dynamic period for the sector.
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19
Structured plan for FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19
Top assets
Lead pipeline drugs
- Marketed / approved
- Marketed / approved
- Marketed / approved
- Marketed / approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 2
- Phase 2
Momentum
Proprietary activity score for Shionogi Inc. (U.S.).
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Recent activity
Latest pipeline, patent, and corporate events for Shionogi Inc. (U.S.).
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Shionogi Inc. (U.S.)?
-
Is Shionogi Inc. (U.S.) publicly traded?
-
What drugs does Shionogi Inc. (U.S.) develop or market?
-
What are the latest developments for Shionogi Inc. (U.S.)?
-
What therapeutic areas does Shionogi Inc. (U.S.) focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.